| Literature DB >> 34583984 |
Reina Tonegawa-Kuji1,2, Noriko Oyama-Manabe3, Ryosuke Aoki4, Shinya Nagayoshi5, Christian Michael Hong Pawhay5,6, Kengo Kusano1,2, Takatomo Nakajima5.
Abstract
OBJECTIVE: We investigated the diagnostic performance of semi-quantitative hyperintensity on T2-weighted short-tau-inversion-recovery black-blood (T2W-STIR-BB) images in identifying active cardiac sarcoidosis (CS) in patients, and compared it with that of 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET).Entities:
Keywords: MRI; cardiomyopathies; diagnostic imaging; positron-emission tomography
Mesh:
Year: 2021 PMID: 34583984 PMCID: PMC8479955 DOI: 10.1136/openhrt-2021-001728
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Representative images illustrating the MSR measurement method. (A) If there was no visibly abnormal high intensity, the ROI was placed at the spleen and the anterior, septal, posterior and lateral wall of the myocardium. (B) If there was a focal area of high signal intensity area in the myocardium, an ROI was placed in the area of hyperintensity within the segment. MSR was calculated as signal intensity of the ROI in the myocardium divided by that of the spleen. MSR, myocardium-to-spleen ratio; ROI, region of interest.
Figure 2Flow diagram illustrating inclusion and exclusion of patients with suspected CS who underwent FDG-PET and CMR. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CS, cardiac sarcoidosis; FDG-PET, 18F-fluoro-2-deoxyglucose positron emission tomography.
Baseline characteristics of 40 patients included in the analysis
| Characteristics | Conventional active | Conventional inactive | P value |
| (n=33) | (n=7) | ||
| Age (years), mean±SD | 64.0±12.0 | 58.4±16.9 | 0.30 |
| Male, n (%) | 15 (46) | 5 (71) | 0.20 |
| CS diagnosed by JCS2016 guideline | |||
| Histological diagnosis | 5 (15) | 0 (0) | 0.36 |
| Clinical diagnosis | 28 (85) | 7 (100) | 0.27 |
| Extracardiac sarcoidosis | |||
| Lung, n (%) | 23 (70) | 4 (57) | 0.41 |
| Eye, n (%) | 2 (6) | 2 (29) | 0.13 |
| Skin, n (%) | 1 (3) | 0 (0) | 0.83 |
| Grandula submandibularis, n (%) | 1 (3) | 0 (0) | 0.83 |
| ECG findings | |||
| Advanced AVB, n (%) | 4 (12) | 0 (0) | |
| Vf, n (%) | 0 (0) | 0 (0) | |
| Sus-VT, n (%) | 2 (6) | 0 (0) | |
| Non-sus VT, n (%) | 20 (61) | 0 (0) | |
| Multifocal frequent PVCs, n (%) | 17 (52) | 3 (43) | 0.50 |
| CRBBB, n (%) | 13 (39) | 1 (14) | 0.21 |
| CLBBB, n (%) | 1 (3) | 0 (0) | 0.83 |
| Pathological Q wave, n (%) | 9 (27) | 1 (14) | 0.43 |
| Abnormal axis deviation | 3 (9) | 1 (14) | 0.55 |
| Any one of Sus-VT, advanced AVB, Vf, non-sus VT observed, n (%) | 23 (70) | 0 (0) | |
| Echocardiography findings | |||
| Basal thinning of the ventricular septum, n (%) | 13 (40) | 0 (0) | 0.48 |
| Other morphological abnormalities of the ventricular walls, n (%) | 18 (55) | 1 (14) | 0.06 |
| LVEF, mean±SD (%) | 47.9±16.0 | 61.4±9.5 | 0.04 |
| LVEF <50% | 19 (58) | 1 (14) | 0.046 |
| Regional wall motion abnormalities | 21 (63) | 1 (14) | 0.02 |
| Follow-up of echocardiography more than 6 months, n (%) | 13 (40) | 1 (14) | 0.21 |
| Follow-up time (months) of patients with multiple echocardiography, median (25%–75%) | 87 (40–116) | 118 | 0.29 |
| Greater than 5% decrease in LVEF, n (%) | 7 (50) | 0 (0) | |
| Gallium-scintigraphy | |||
| Gallium-scintigraphy performed, n (%) | 28 (85) | 6 (86) | 0.72 |
| Positive uptake of gallium in the myocardium, n (%) | 7 (21) | 0 (0) | |
| Laboratory data | |||
| ACE (U/L), mean±SD | 12.3±3.3 | 17.0±1.5 | 0.11 |
| Lysozyme (μg/mL), median (25%–75%) | 5.9 (4.7–6.5) | 8.2 (6.4–10.6) | 0.06 |
| sIL-2R (U/mL), median (25%–75%) | 260 (244–332) | 486 (292–763) | 0.03 |
| ACE positive, n (%) | 4 (12) | 0 (0) | |
| Lysozyme positive, n (%) | 16 (49) | 0 (0) | |
| sIL-2R positive, n (%) | 8 (24) | 0 (0) | |
| Any one of ACE, lysozyme or sIL-2R positive, n (%) | 20 (61) | 0 (0) | |
| Brain natriuretic peptide (pg/mL), median (25%–75%) | 19.1 (14.1–61.9) | 93.4 (29.6–469.8) | 0.08 |
| High-sensitivity troponin value available, n (%) | 13 (39) | 3 (43) | 1.00 |
| High-sensitivity troponin (ng/mL), median (25%–75%) | 0.006 (0.004–0.026) | 0.024 (0.019–0.034) | 0.14 |
| Baseline medications | |||
| β-blockers, n (%) | 15 (45) | 1 (14) | 0.21 |
| ACE inhibitors, n (%) | 8 (24) | 2 (29) | 1.00 |
| ARB, n (%) | 7 (21) | 1 (14) | 1.00 |
| Diuretics, n (%) | 12 (36) | 0 (0) | 0.08 |
| Antiarrhythmic drugs other than β-blockers, n (%) | 3 (9) | 0 (0) | 1.00 |
AVB, atrioventricular block; CLBBB, complete left bundle branch block; CRBBB, complete right bundle branch block; CS, cardiac sarcoidosis; ECG, electrocardiogram; JCS, Japanese Circulation Society; LVEF, left ventricular ejection fraction; non-sus VT, non-sustained ventricular tachycardia; PVC, premature ventricular contraction; sIL-2R, soluble interleukin 2 receptor; sus-VT, sustained ventricular tachycardia; Vf, ventricular fibrillation.
Results of the FDG-PET and CMR studies in patients with CS
| Characteristics | Conventional active group (n=33) | Conventional inactive group (n=7) | P value |
| FDG-PET positive, n (%) | 23 (70) | 2 (29) | 0.06 |
| T2W-STIR-BB in CMR positive by quantitative analysis using MSR, n (%) | 26 (79) | 4 (57) | 0.23 |
| T2W-STIR-BB in CMR positive by visual analysis, n (%) | 21 (64) | 4 (57) | 0.53 |
| LGE in CMR compatible with CS positive, n (%) | 32 (100) | 6 (100) | 1.0 |
CMR, cardiac magnetic resonance; CS, cardiac sarcoidosis; FDG-PET, 18F-fluoro-2-deoxyglucose positron emission tomography; LGE, late gadolinium enhancement; MSR, myocardium-to-spleen ratio; T2W-STIR-BB, T2-weighted short-tau-inversion-recovery black-blood.
Figure 3Distribution of segments with abnormal high signal intensity in T2W-STIR-BB, LGE and FDG uptake in CS patients with CS. The numbers show the positive ratios in each segment. FDG-PET, 18F-fluoro-2-deoxyglucose positron emission tomography; LGE, late gadolinium enhancement; T2W-STIR-BB, T2-weighted short-tau-inversion recovery black-blood images.
Figure 4Representative CMR and FDG-PET images of the conventional active and inactive group. Case1: conventional positive case with all positives on T2W-STIR-BB, LGE and FDG-PET. The patient was in his/her 70s, with a familial history of sudden cardiac death of his/her child in his/her 40s. At first, his/her cardiac function was normal but then dropped to a left ventricular ejection fraction of 40% with asynergy and thinning in the anteroseptal wall. T2W-STIR-BB image is transmurally positive in the basal to mid-level of the anteroseptal wall. Late gadolinium enhancement is present at the same location of high signal intensity in the T2W-STIR-BB image. Maximum intensity projection FDG-PET image shows strong FDG uptake at the anteroseptal myocardium and hilar and mediastinal lymph node. Case 2: conventional inactive case with all positives on T2W-STIR-BB, LGE and FDG-PET in an asymptomatic patient in his/her 40s. T2W-STIR-BB image is positive in the epicardial side of the basal level of the septal wall in which MSR is 0.67. Spotty late gadolinium enhancement is present at the epicardial side of the basal level of the right ventricular junction. Maximum intensity projection FDG-PET image shows strong FDG uptake by the myocardium and hilar and mediastinal lymph nodes. Even though the patient did not have any clinical symptoms to suspect active CS, positive findings on both T2W-STIR-BB and FDG-PET suggest active myocardial inflammation. CMR, cardiac magnetic resonance; CS, cardiac sarcoidosis; FDG-PET, 18F-fluoro-2-deoxyglucose positron emission tomography; LGE, late gadolinium enhancement; MSR, myocardium-to-spleen ratio; T2W-STIR-BB, T2-weighted short-tau-inversion-recovery black-blood.
Figure 5Graphs illustrating diagnostic performance of FDG-PET and T2W-STIR-BB imaging when we used positive findings in conventional methods as the gold standard of CS activity. Sensitivity, specificity and accuracy of T2W-STIR-BB imaging were statistically non-inferior to those of FDG-PET among all comparisons. CS, cardiac sarcoidosis; FDG-PET, 18F-fluoro-2-deoxyglucose positron emission tomography; T2W-STIR-BB, T2-weighted short-tau-inversion-recovery black-blood images.
Diagnostic performance of high signal intensity on T2-weighted short-tau-inversion recovery black-blood compared with 18F-fluoro-2-deoxyglucose positron emission tomography
| Quantitative analysis (%) | Qualitative analysis (%) | P value | |
| Sensitivity | 92 | 60 | 0.005 |
| Specificity | 53 | 33 | 0.180 |
| Accuracy | 78 | 50 | 0.041 |
| Positive predictive value | 77 | 60 | – |
| Negative predictive value | 80 | 33 | – |